Expression of Epithelial Alarmin Receptor on Innate Lymphoid Cells Type 2 in Eosinophilic Chronic Obstructive Pulmonary Disease.

IF 1.8 Q3 RESPIRATORY SYSTEM
Katarzyna Królak-Nowak, Marta Wierzbińska, Aleksandra Żal, Adam Antczak, Damian Tworek
{"title":"Expression of Epithelial Alarmin Receptor on Innate Lymphoid Cells Type 2 in Eosinophilic Chronic Obstructive Pulmonary Disease.","authors":"Katarzyna Królak-Nowak, Marta Wierzbińska, Aleksandra Żal, Adam Antczak, Damian Tworek","doi":"10.3390/arm92050039","DOIUrl":null,"url":null,"abstract":"<p><p>Studies have shown that eosinophilic COPD (eCOPD) is a distinct phenotype of the disease. It is well established that innate lymphoid cells are involved in the development of eosinophilic inflammation. Interleukin(IL)-25, thymic stromal lymphopoietin (TSLP) and IL-33 are a group of cytokines produced by epithelium in response to danger signals, e.g., cigarette smoke, and potent activators of ILC2s. In the present study, we examined circulating and sputum ILC2 numbers and expression of intracellular IL-5 as well as receptors for TSLP, IL-33 and IL-25 by ILC2s in non-atopic COPD patients with and without (neCOPD) airway eosinophilic inflammation and healthy smokers. In addition, we examined the association between ILC2s and clinical indicators of COPD burden (i.e., symptom intensity and risk of exacerbations). ILC2s were enumerated in peripheral blood and induced sputum by means of flow cytometry. We noted significantly greater numbers of airway IL-5<sup>+</sup>ILC2s and TSLPR<sup>+</sup>ILC2s in eCOPD compared with neCOPD (<i>p</i> < 0.05 and <i>p</i> < 0.01, respectively) and HSs (<i>p</i> < 0.001 for both). In addition, we showed that IL-5<sup>+</sup>ILC2s, IL-17RB<sup>+</sup>ILC2s and ST2<sup>+</sup>ILC2s are significantly increased in the sputum of eCOPD patients compared with HSs. In all COPD patients, sputum ILC2s positively correlated with sputum eosinophil percentage (r = 0.48, <i>p</i> = 0.002). We did not find any significant correlations between sputum ILC2s and dyspnea intensity as measured by the modified Medical Research Council scale (mMRC) and symptom intensity measured by the COPD Assessment Test (CAT). These results suggest the involvement of epithelial alarmin-activated ILC2s in the pathobiology of eosinophilic COPD.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"92 5","pages":"429-443"},"PeriodicalIF":1.8000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11505438/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/arm92050039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Studies have shown that eosinophilic COPD (eCOPD) is a distinct phenotype of the disease. It is well established that innate lymphoid cells are involved in the development of eosinophilic inflammation. Interleukin(IL)-25, thymic stromal lymphopoietin (TSLP) and IL-33 are a group of cytokines produced by epithelium in response to danger signals, e.g., cigarette smoke, and potent activators of ILC2s. In the present study, we examined circulating and sputum ILC2 numbers and expression of intracellular IL-5 as well as receptors for TSLP, IL-33 and IL-25 by ILC2s in non-atopic COPD patients with and without (neCOPD) airway eosinophilic inflammation and healthy smokers. In addition, we examined the association between ILC2s and clinical indicators of COPD burden (i.e., symptom intensity and risk of exacerbations). ILC2s were enumerated in peripheral blood and induced sputum by means of flow cytometry. We noted significantly greater numbers of airway IL-5+ILC2s and TSLPR+ILC2s in eCOPD compared with neCOPD (p < 0.05 and p < 0.01, respectively) and HSs (p < 0.001 for both). In addition, we showed that IL-5+ILC2s, IL-17RB+ILC2s and ST2+ILC2s are significantly increased in the sputum of eCOPD patients compared with HSs. In all COPD patients, sputum ILC2s positively correlated with sputum eosinophil percentage (r = 0.48, p = 0.002). We did not find any significant correlations between sputum ILC2s and dyspnea intensity as measured by the modified Medical Research Council scale (mMRC) and symptom intensity measured by the COPD Assessment Test (CAT). These results suggest the involvement of epithelial alarmin-activated ILC2s in the pathobiology of eosinophilic COPD.

嗜酸性粒细胞慢性阻塞性肺病 2 型先天淋巴细胞上皮 Alarmin 受体的表达
研究表明,嗜酸性粒细胞慢性阻塞性肺病(eCOPD)是该病的一种独特表型。先天性淋巴细胞参与了嗜酸性粒细胞炎症的发展,这一点已得到公认。白细胞介素(IL)-25、胸腺基质淋巴细胞生成素(TSLP)和 IL-33 是上皮细胞针对危险信号(如香烟烟雾)产生的一组细胞因子,也是 ILC2 的强效激活剂。在本研究中,我们检测了有或没有气道嗜酸性粒细胞炎症(neCOPD)的非变应性 COPD 患者和健康吸烟者的循环和痰液 ILC2 数量、细胞内 IL-5 的表达以及 ILC2 的 TSLP、IL-33 和 IL-25 受体。此外,我们还研究了 ILC2s 与慢性阻塞性肺病负担的临床指标(即症状强度和恶化风险)之间的关联。我们通过流式细胞术对外周血和诱导痰中的 ILC2 进行了计数。我们发现,与新慢性阻塞性肺病(p < 0.05 和 p < 0.01)和慢性阻塞性肺病(p < 0.001)相比,eCOPD 患者气道 IL-5+ILC2s 和 TSLPR+ILC2s 的数量明显增多。此外,我们还发现,与 HSs 相比,eCOPD 患者痰中的 IL-5+ILC2s、IL-17RB+ILC2s 和 ST2+ILC2s 显著增加。在所有 COPD 患者中,痰中 ILC2s 与痰中嗜酸性粒细胞百分比呈正相关(r = 0.48,p = 0.002)。我们没有发现痰液 ILC2 与改良医学研究委员会量表(mMRC)测量的呼吸困难强度和慢性阻塞性肺病评估测试(CAT)测量的症状强度之间有任何明显的相关性。这些结果表明,上皮alarmin激活的ILC2参与了嗜酸性粒细胞慢性阻塞性肺病的病理生物学研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in respiratory medicine
Advances in respiratory medicine RESPIRATORY SYSTEM-
CiteScore
2.60
自引率
0.00%
发文量
90
期刊介绍: "Advances in Respiratory Medicine" is a new international title for "Pneumonologia i Alergologia Polska", edited bimonthly and addressed to respiratory professionals. The Journal contains peer-reviewed original research papers, short communications, case-reports, recommendations of the Polish Respiratory Society concerning the diagnosis and treatment of lung diseases, editorials, postgraduate education articles, letters and book reviews in the field of pneumonology, allergology, oncology, immunology and infectious diseases. "Advances in Respiratory Medicine" is an open access, official journal of Polish Society of Lung Diseases, Polish Society of Allergology and National Research Institute of Tuberculosis and Lung Diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信